NCT04165330: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for part 1 of the study; Patients must have at least one prior line of standard therapy
Exclusions: Patients with untreated, active brain metastases; Patients with leptomeningeal disease

Comments are closed.

Up ↑